Stockreport

Xencor to regain rights from J&J for plamotamab [Seeking Alpha]

Xencor, Inc.  (XNCR) 
Last xencor, inc. earnings: 2/24 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.xencor.com/investor-relations
PDF Janssen and Xencor entered into a partnership in 2021 to develop and commercialize plamotamab and novel B-cell targeting bispecific antibodies. Xencor had Recommended [Read more]